Topotecan and cladribine with filgrastim support in relapsed, refractory and poor prognosis leukemias: A phase I-II study

被引：0
作者：
Silverman, LR [1 ]
Isola, L [1 ]
Brenner, R [1 ]
Gabrilove, J [1 ]
Mandeli, J [1 ]
机构：
[1] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6724
引用
收藏
页码：613S / 613S
页数：1
相关论文
共 50 条
  • [41] A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia
    Cooper, BW
    Donaher, E
    Lazarus, HM
    Green, SB
    Gosky, DM
    Rosenthal, NS
    Berger, SJ
    Li, XL
    Ingalls, ST
    Hoppel, CL
    Gerson, SL
    LEUKEMIA RESEARCH, 2003, 27 (01) : 35 - 44
  • [42] Phase I study of bortezomib in refactory or relapsed acute leukemias
    Cortes, J
    Thomas, D
    Koller, C
    Giles, F
    Estey, E
    Faderl, S
    Garcia-Manero, G
    McConkey, D
    Ruiz, SL
    Guerciolini, R
    Wright, J
    Kantarjian, H
    CLINICAL CANCER RESEARCH, 2004, 10 (22) : 7787 - 7787
  • [43] A Phase I-II Evaluation of Veliparib (NSC # 737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix An NRG Oncology/Gynecologic Oncology Group Study
    Kunos, Charles
    Deng, Wei
    Dawson, Dawn
    Lea, Jayanthi S.
    Zanotti, Kristine M.
    Gray, Heidi J.
    Bender, David P.
    Guaglianone, Perry P.
    Carter, Jori S.
    Moore, Kathleen N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (03) : 484 - 492
  • [44] PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN (TPT), A-TOPOISOMERASE (TOPO) I-INHIBITOR, IN PATIENTS (PTS) WITH REFRACTORY LEUKEMIAS
    ADJEI, AA
    ROWINSKY, EK
    DONEHOWER, RC
    JONES, RJ
    BURKE, PJ
    GORE, S
    GROCHOW, LB
    KAUFMANN, SH
    BLOOD, 1993, 82 (10) : A443 - A443
  • [45] PHASE-I STUDY OF TOPOTECAN, A NEW TOPOISOMERASE-I INHIBITOR, IN PATIENTS WITH REFRACTORY OR RELAPSED ACUTE-LEUKEMIA
    KANTARJIAN, HM
    BERAN, M
    ELLIS, A
    ZWELLING, L
    OBRIEN, S
    CAZENAVE, L
    KOLLER, C
    RIOS, MB
    PLUNKETT, W
    KEATING, MJ
    ESTEY, EH
    BLOOD, 1993, 81 (05) : 1146 - 1151
  • [46] A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Mullerian tumors
    Penson, RT
    Supko, JG
    Seiden, MV
    Fuller, AF
    Berkowitz, RS
    Goodman, A
    Campos, SM
    MacNeill, KM
    Cook, S
    Matulonis, UA
    CANCER, 2001, 92 (05) : 1156 - 1167
  • [47] A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer
    Masters, GA
    Mauer, AM
    Hoffman, PC
    Wyka, D
    Samuels, BL
    Krauss, SA
    Watson, S
    Golomb, H
    Vokes, EE
    ANNALS OF ONCOLOGY, 1998, 9 (06) : 677 - 680
  • [48] Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies
    Hanna, NH
    Gordon, MS
    Fife, K
    Sandler, AB
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (04): : 337 - 339
  • [49] A phase I and pharmacodynamic study of sequential topotecan and etoposide (TE) in adult patients with refractory/relapsed acute leukemia (RAL).
    Donaher, E
    Berger, S
    Hoppel, C
    Lazarus, H
    Gerson, S
    Cooper, B
    BLOOD, 1998, 92 (10) : 234A - 234A
  • [50] A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia
    Cooper, BW
    Veal, GJ
    Radivoyevitch, T
    Tilby, MJ
    Meyerson, HJ
    Lazarus, HM
    Koc, ON
    Creger, RJ
    Pearson, G
    Nowell, GM
    Gosky, D
    Ingalls, ST
    Hoppel, CL
    Gerson, SL
    CLINICAL CANCER RESEARCH, 2004, 10 (20) : 6830 - 6839
12345